- This week, we recorded two new campaigns. While one of the targeted shares ended the week about 29.5% lower, the other is unchanged.
- We highlight new $2bn target of Citron which is allegedly yet another stock trying to make the most out of the COVID-19 situation. We also note another Citron development as they released an update on GSX Techedu, US-listed education company in China. Citron provides further supposed evidence which should support its initial thesis. They called for the SEC to investigate.
- Furthermore, we look at WUBA, the target of Grizzly Research. This allegedly China Hustle 2.0 stock might be in the process of getting bought out. Grizzly believes this is merely a ruse.
- Lastly, we briefly examine if, as proposed by Marc Cohodes, there should be a ten days minimum holding period for those that publicly advocate a long or short position.
However, before we dive into the new short campaigns, we will leave here Friday's tweet by a very famous CEO, which left us scratching our heads and thinking if we should include it in our database among short calls:
Tesla stock price is too high imo— Elon Musk (@elonmusk) May 1, 2020
Note that Tesla closed about 10.3% lower on the day of this tweet.
Another COVID-19 related short report
At least this is what Citron Research had in focus as they targeted Inovio Pharmaceuticals (INO), a $2bn biotech firm this week. Citron did not hold back and called INO a public version of Theranos, the infamous biotech whose founder is facing federal fraud charges.
The reason for this allegation were the circumstances under which INO should have developed a COVID-19 vaccine. The company claims it has used its proprietary computer algorithm to develop a vaccine in just...
(Get full weekly report and stay on top of activist short selling developments - Join Breakout Point).
* Note: Presented data and analytics is as of available on 2020-05-02, UTC 12:00.
The services and any information provided by Breakout Point or on the Breakout Point website shall not be, or construed to be any advice, guidance or recommendation to take, or not to take, any actions or decisions in relation to any investment, divestment or the purchase or sale of any assets, shares, participations or any securities of any kind. Any information obtained through Breakout Point and its services should never be used as a substitute for financial or other professional advice. Any decisions based on, or taken by use of, information obtained through Breakout Point and by its services are entirely at own risk.